Rapid Dose Therapeutics's long-term debt is $1.9M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
Rapid Dose Therapeutics (RDTCF) currently reports a long-term debt of $1.9M as of August 2026. That compares with $4.5M in the prior-year period — down 58.3% year over year. Use the charts on this page to explore Rapid Dose Therapeutics's long-term debt history and peer comparisons.
Rapid Dose Therapeutics's long-term debt decreased from $4.5M to $1.9M — a 58.3% year-over-year decrease (period ending August 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Rapid Dose Therapeutics reported $1.9M in long-term debt as of August 2026. That compares with $4.5M in the prior-year period — down 58.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current long-term debt of $1.9M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Rapid Dose Therapeutics, and consider following RDTCF for alerts when major investors trade the stock.
Rapid Dose Therapeutics is classified in the Healthcare sector. On long-term debt, it currently shows $1.9M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing RDTCF with unrelated industries.